Time in range

Biomarker4 papers1 finding

Human trial1
Humans1

Interventions

1

Semaglutide

downin humans1Very low certainty

1 study

Semaglutide decreases time in range in humans (median change -3.6% vs. 1.5%).
Human trialfollowing discontinuation vs placebo12 weeks
Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study · Diabetes, obesity & metabolism · 31 Aug 2026

Semaglutide →

Latest

23

BMJ OpenResearch10 h

Effects of ultra-processed food reduction intervention on postprandial glucose and glycaemic variability in Korean young adults: study protocol for the ULTRA-CGM randomised controlled trial

Journal of Diabetes Science and TechnologyReview26 Sep

Combining Contingency Management With Continuous Glucose Monitoring to Support Type 2 Diabetes Prevention and Care

Type 2 diabetes

NutrientsHuman trial15 Sep

Time-Restricted Eating Is Feasible and Acceptable and Improves Glycemic Control in Veterans with Spinal Cord Injury and Obesity: A Pilot Trial

Dietary restriction

Frontiers in EndocrinologyReview9 Sep

Can continuous glucose monitoring-derived glycemic variability predict retinal neurodegeneration earlier than HbA1c in patients without clinically apparent retinopathy?

Journal of Diabetes ResearchHumans8 Sep

Postpartum Glycaemic Phenotype and Continuous Glucose Monitoring at 4-6 Years After Gestational Diabetes Defined by Different Diagnostic Criteria

Diabetes, Obesity & MetabolismHuman trial1 Sep

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study

MedicinaHumans27 Aug

Limited Discriminatory Capacity of Continuous Glucose Monitoring in Prediabetes and Increased Diabetes Risk: A Cross-Sectional Study

ADA Scientific Sessions 2026 AbstractHumans8 Jun

Overdiagnosis of Prediabetes by GMI: Use of Updated GMI Improves Alignment with HbA1c and Time Above Range

ADA Scientific Sessions 2026 AbstractHumans7 Jun

Dynamic CGM Models to Predict GDM: A GO MOMs Analysis

ADA Scientific Sessions 2026 AbstractHuman trial6 Jun

Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial